Clinical comprehensive evaluation of bortezomib in the treatment of multiple myeloma
Objective:To comprehensively evaluate the clinical safety,efficacy,economy,innovation,suitability and accessibility of bortezomib for the treatment of multiple myeloma.Methods:The indicators were analyzed in an integrated manner through evidence from all levels of sources.Results:Six systematic reviews/mata-analysis and 5 pharmacoeconomic studies were enrolled.The overall response rate in multiple myeloma patients treated with bortezomib were better than without,the incidence of adverse drug reaction was 64.06%,but the incidence of thrombocytopenia and peripheral neuropathy was higher.This study showed that bortezomib was convenient for storage with sufficient production capacity,and some products were good affordable,but lacked innovation data.Conclusion:Bortezomib is safe and effective,with good suitability and accessibility and some schemes are cost-effective.
万方数据
维普
